Our Pipeline Featuring AVERSA™ Abuse-Deterrent Technology

Our lead platform technology, is our AVERSA™, is an abuse-deterrent transdermal technology that can be incorporated into any transdermal delivery system designed to enhance the safety profile of patch-based medications. to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. We believe AVERSA is compatible with virtually any transdermal patch on the market today, offering a scalable solution to reduce the risk of misuse—particularly in the context of opioid-based therapies.

​

Our lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with our AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. We plan to follow the development of AVERSA Fentanyl with the development of additional abuse deterrent transdermal products for pharmaceuticals that have a risk or history of abuse, misuse or accidental exposure such as opioids and stimulant drugs. Specifically, we have expanded our development pipeline to include AVERSA Buprenorphine and AVERSA Methylphenidate. In addition, we are developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery.